Summarized by Masters of Longevity from FDA - Drugs.
FDA approved daratumumab with hyaluronidase plus chemotherapy for newly diagnosed AL amyloidosis.
Key Takeaways
- The FDA granted accelerated approval for daratumumab with hyaluronidase.
- The approval is for use with bortezomib, cyclophosphamide, and dexamethasone.
- Accelerated approval requires confirmatory trials and is not definitive proof.
